How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,871 results for

Follicle Stimulating Hormone

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Targeting the Follicle Stimulating Hormone Receptor (FSHR) To Treat Fertility Disorders (PubMed)

Targeting the Follicle Stimulating Hormone Receptor (FSHR) To Treat Fertility Disorders 27096038 2016 04 20 2018 11 13 1948-5875 7 4 2016 Apr 14 ACS medicinal chemistry letters ACS Med Chem Lett Targeting the Follicle Stimulating Hormone Receptor (FSHR) To Treat Fertility Disorders. 345-7 10.1021/acsmedchemlett.6b00082 Abdel-Magid Ahmed F AF Therachem Research Medilab (India) Pvt. Ltd. , Jaipur, India. eng Journal Article 2016 03 04 United States ACS Med Chem Lett 101521073 1948-5875 2016 02 25

Full Text available with Trip Pro

2016 ACS medicinal chemistry letters

102. Extracellular Signal-regulated Kinase (ERK)-dependent Phosphorylation of Y-Box-binding Protein 1 (YB-1) Enhances Gene Expression in Granulosa Cells in Response to Follicle-stimulating Hormone (FSH) (PubMed)

Extracellular Signal-regulated Kinase (ERK)-dependent Phosphorylation of Y-Box-binding Protein 1 (YB-1) Enhances Gene Expression in Granulosa Cells in Response to Follicle-stimulating Hormone (FSH) Within the ovarian follicle, immature oocytes are surrounded and supported by granulosa cells (GCs). Stimulation of GCs by FSH leads to their proliferation and differentiation, events that are necessary for fertility. FSH activates multiple signaling pathways to regulate genes necessary (...) for follicular maturation. Herein, we investigated the role of Y-box-binding protein-1 (YB-1) within GCs. YB-1 is a nucleic acid binding protein that regulates transcription and translation. Our results show that FSH promotes an increase in the phosphorylation of YB-1 on Ser(102) within 15 min that is maintained at significantly increased levels until ∼8 h post treatment. FSH-stimulated phosphorylation of YB-1(Ser(102)) is prevented by pretreatment of GCs with the PKA-selective inhibitor PKA inhibitor (PKI

Full Text available with Trip Pro

2016 The Journal of biological chemistry

103. Follicle Stimulating Hormone

Follicle Stimulating Hormone Follicle Stimulating Hormone Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Follicle Stimulating Hormone (...) Follicle Stimulating Hormone Aka: Follicle Stimulating Hormone , Serum FSH II. Normal Levels Male: <20 mIU/ml Female: <25 mIU/ml (Higher in mid-cycle surge) : 30 to 250 mIU/ml III. Indications Not necessary to confirm diagnosis Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Follicle Stimulating Hormone." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database

2018 FP Notebook

104. FOLLICLE-STIMULATING HORMONE RECEPTOR IS EXPRESSED BY MOST OVARIAN CANCER SUBTYPES AND IS A SAFE AND EFFECTIVE IMMUNOTHERAPEUTIC TARGET. (PubMed)

FOLLICLE-STIMULATING HORMONE RECEPTOR IS EXPRESSED BY MOST OVARIAN CANCER SUBTYPES AND IS A SAFE AND EFFECTIVE IMMUNOTHERAPEUTIC TARGET. To define the safety and effectiveness of T cells redirected against follicle-stimulating hormone receptor (FSHR)-expressing ovarian cancer cells.FSHR expression was determined by Western blotting, immunohistochemistry, and qPCR in 77 human ovarian cancer specimens from 6 different histologic subtypes and 20 human healthy tissues. The effectiveness of human T

Full Text available with Trip Pro

2016 Clinical Cancer Research

105. Featured Article: Transcriptional landscape analysis identifies differently expressed genes involved in follicle-stimulating hormone induced postmenopausal osteoporosis (PubMed)

Featured Article: Transcriptional landscape analysis identifies differently expressed genes involved in follicle-stimulating hormone induced postmenopausal osteoporosis Osteoporosis is a disorder associated with bone tissue reorganization, bone mass, and mineral density. Osteoporosis can severely affect postmenopausal women, causing bone fragility and osteoporotic fractures. The aim of the current study was to compare blood mRNA profiles of postmenopausal women with and without osteoporosis (...) in a follicle-stimulating hormone activated network of increased osteoclast activity and hypogonadal bone loss. The differentially expressed genes identified in this study may contribute to future research of postmenopausal osteoporosis blood biomarkers.

Full Text available with Trip Pro

2016 Experimental Biology and Medicine

106. Revisiting the expression and function of follicle-stimulation hormone receptor in human umbilical vein endothelial cells (PubMed)

Revisiting the expression and function of follicle-stimulation hormone receptor in human umbilical vein endothelial cells Expression of follicle-stimulation hormone receptor (FSHR) is confined to gonads and at low levels to some extragonadal tissues like human umbilical vein endothelial cells (HUVEC). FSH-FSHR signaling was shown to promote HUVEC angiogenesis and thereafter suggested to have an influential role in pregnancy. We revisited hereby the expression and functionality of FSHR in HUVECs

Full Text available with Trip Pro

2016 Scientific reports

107. SMAD3 Regulates Follicle-stimulating Hormone Synthesis by Pituitary Gonadotrope Cells in Vivo (PubMed)

SMAD3 Regulates Follicle-stimulating Hormone Synthesis by Pituitary Gonadotrope Cells in Vivo Pituitary follicle-stimulating hormone (FSH) is an essential regulator of fertility in females and of quantitatively normal spermatogenesis in males. Pituitary-derived activins are thought to act as major stimulators of FSH synthesis by gonadotrope cells. In vitro, activins signal via SMAD3, SMAD4, and forkhead box L2 (FOXL2) to regulate transcription of the FSHβ subunit gene (Fshb). Consistent (...) knock-out females were hypogonadal, acyclic, and sterile and had thread-like uteri; their ovaries lacked antral follicles and corpora lutea. Knock-out males were fertile but had reduced testis weights and epididymal sperm counts. These phenotypes were consistent with those of Fshb knock-out mice. Indeed, pituitary Fshb mRNA levels were nearly undetectable in both male and female knock-outs. In contrast, gonadotropin-releasing hormone receptor mRNA levels were significantly elevated in knock-outs

Full Text available with Trip Pro

2016 The Journal of biological chemistry

108. c-JUN Dimerization Protein 2 (JDP2) Is a Transcriptional Repressor of Follicle-stimulating Hormone β (FSHβ) and Is Required for Preventing Premature Reproductive Senescence in Female Mice (PubMed)

c-JUN Dimerization Protein 2 (JDP2) Is a Transcriptional Repressor of Follicle-stimulating Hormone β (FSHβ) and Is Required for Preventing Premature Reproductive Senescence in Female Mice Follicle-stimulating hormone (FSH) regulates follicular growth and stimulates estrogen synthesis in the ovaries. FSH is a heterodimer consisting of an α subunit, also present in luteinizing hormone, and a unique β subunit, which is transcriptionally regulated by gonadotropin-releasing hormone 1 (GNRH (...) in a complex with c-JUN. GNRH treatment induced c-FOS to replace JDP2 as a c-JUN binding partner, forming transcriptionally active AP-1. Subsequently, rapid c-FOS degradation enabled reformation of the JDP2 complex. In vivo studies revealed that JDP2 null male mice have normal reproductive function, as expected from a negative regulator of the FSH hormone. Female JDP2 null mice, however, exhibited early puberty, observed as early vaginal opening, larger litters, and early reproductive senescence. JDP2 null

Full Text available with Trip Pro

2016 The Journal of biological chemistry

109. Long-chain unsaturated fatty acids reduce the transcriptional activity of the rat follicle-stimulating hormone β-subunit gene (PubMed)

Long-chain unsaturated fatty acids reduce the transcriptional activity of the rat follicle-stimulating hormone β-subunit gene Here, we assessed the effects of long-chain fatty acids (LCFAs) and the LCFA receptor agonist GW9508 on the transcription of the gonadotropin subunit genes Cga, Lhb and Fshb because LCFA receptor GPR120 was observed in mouse gonadotropes in our recent study. A transcription assay using LβT2 cells demonstrated that LCFAs, oleic acid, α-linolenic acid, docosahexaenoic

Full Text available with Trip Pro

2016 The Journal of reproduction and development

110. Transcription of follicle-stimulating hormone subunit genes is modulated by porcine LIM homeobox transcription factors, LHX2 and LHX3 (PubMed)

Transcription of follicle-stimulating hormone subunit genes is modulated by porcine LIM homeobox transcription factors, LHX2 and LHX3 The LIM-homeobox transcription factors LHX2 and LHX3s (LHX3a and LHX3b) are thought to be involved in regulating the pituitary glycoprotein hormone subunit genes Cga and Fshβ. These two factors show considerable differences in their amino acid sequences for DNA binding and protein-protein interactions and in their vital function in pituitary development. Hence (...) . There were alternative binding sites to either gene in addition to similar differences observed in the Cga promoter. The transcriptional activities of LHX2 and LHX3s according to a reporter assay showed cell-type dependent activity with repression in the pituitary gonadotrope lineage LβT2 cells and stimulation in Chinese hamster ovary lineage CHO cells. Reactivity of LHX2 and LHX3s was observed in all regions, and differences were observed in the 5'-upstream region of Fshβ. However, immunohistochemistry

Full Text available with Trip Pro

2016 The Journal of reproduction and development

111. Analysis of the Relationship between Estradiol and Follicle-Stimulating Hormone Concentrations and Polymorphisms of Apolipoprotein E and LeptinGenes in Women Post-Menopause (PubMed)

Analysis of the Relationship between Estradiol and Follicle-Stimulating Hormone Concentrations and Polymorphisms of Apolipoprotein E and LeptinGenes in Women Post-Menopause Menopause is the permanent cessation of menstruation due to loss of ovarian follicular activity. A review of the available literature indicates that correlations between the changes that take place in a woman's body after menopause and different genetic variants are still being sought.The study was conducted in 252 women who (...) had completed physiological menopause. The women were divided into groups according to the time elapsed since menopause. The total concentrations of estradiol and follicle-stimulating hormone were determined by means of electrochemiluminescence. The apolipoprotein E (APOE) and lepitn (LEP) genotypes were determined by real-time PCR and polymerase chain reaction-restriction fragment length polymorphism, respectively.We observed that people with the APOE3/E3 genotype entered menopause

Full Text available with Trip Pro

2016 International journal of environmental research and public health

112. Forkhead Box O member FOXO1 Regulates the Majority of Follicle-Stimulating Hormone Responsive Genes in Ovarian Granulosa Cells (PubMed)

Forkhead Box O member FOXO1 Regulates the Majority of Follicle-Stimulating Hormone Responsive Genes in Ovarian Granulosa Cells FSH promotes maturation of ovarian follicles. One pathway activated by FSH in granulosa cells (GCs) is phosphatidylinositol-3 kinase/AKT. The AKT target FOXO1 is reported to function primarily as a repressor of FSH genes, including Ccnd2 and Inha. Based on its broad functions in other tissues, we hypothesized that FOXO1 may regulate many more GC genes. We transduced GCs

Full Text available with Trip Pro

2016 Molecular and cellular endocrinology

113. Follicle-stimulating Hormone (FSH) Phosphorylation of Protein Kinase B (AKT) Remains Controversial (PubMed)

Follicle-stimulating Hormone (FSH) Phosphorylation of Protein Kinase B (AKT) Remains Controversial 27371562 2016 11 10 2018 12 02 1083-351X 291 27 2016 Jul 01 The Journal of biological chemistry J. Biol. Chem. Follicle-stimulating Hormone (FSH) Phosphorylation of Protein Kinase B (AKT) Remains Controversial. 14385 10.1074/jbc.L116.726943 Stocco Carlos C Department of Physiology and Biophysics, University of Illinois, Chicago, Illinois 60612 costocco@uic.edu. eng R56 HD086054 HD NICHD NIH HHS (...) United States Letter Comment United States J Biol Chem 2985121R 0021-9258 9002-68-0 Follicle Stimulating Hormone EC 2.7.11.1 Proto-Oncogene Proteins c-akt IM J Biol Chem. 2016 Feb 26;291(9):4547-60 26702053 Follicle Stimulating Hormone metabolism Granulosa Cells metabolism Humans Phosphorylation Proto-Oncogene Proteins c-akt metabolism Signal Transduction 2016 7 3 6 0 2016 7 3 6 0 2016 11 11 6 0 ppublish 27371562 291/27/14385 10.1074/jbc.L116.726943 PMC4933191 Methods Mol Biol. 2007;365:23-38

Full Text available with Trip Pro

2016 The Journal of biological chemistry

114. Ascorbic acid treatment elevates follicle stimulating hormone and testosterone plasma levels and enhances sperm quality in albino Wistar rats. (PubMed)

Ascorbic acid treatment elevates follicle stimulating hormone and testosterone plasma levels and enhances sperm quality in albino Wistar rats. Infertility issues have been linked to the effect of oxidative reaction in the reproductive system. This study evaluated the effect of ascorbic acid, on fertility parameters of male albino Wistar rats was studied.Eighteen albino Wistar rats weighed between 178 g and 241 g were used, randomly assigned into three groups. Group 1 was the control group; oral (...) gavaged 5 ml of distilled water; Groups 2 and 3 were administered medium dose (250 mg/kg) and high dose of ascorbic acid (400 mg/kg), respectively; twice daily for 21 days. Blood samples were obtained by cardiac puncture, and blood serum was obtained for hormonal assay, and the testes were harvested for sperm analysis.Follicle stimulating hormone levels significantly increased in the high-dose group as compared to both the control and medium dose groups. Luteinizing hormone levels in the medium dose

Full Text available with Trip Pro

2016 Nigerian medical journal : journal of the Nigeria Medical Association Controlled trial quality: uncertain

115. Population Pharmacokinetic Modelling of FE 999049, a Recombinant Human Follicle-Stimulating Hormone, in Healthy Women After Single Ascending Doses (PubMed)

Population Pharmacokinetic Modelling of FE 999049, a Recombinant Human Follicle-Stimulating Hormone, in Healthy Women After Single Ascending Doses The purpose of this analysis was to develop a population pharmacokinetic model for a novel recombinant human follicle-stimulating hormone (FSH) (FE 999049) expressed from a human cell line of foetal retinal origin (PER.C6(®)) developed for controlled ovarian stimulation prior to assisted reproductive technologies.Serum FSH levels were measured

Full Text available with Trip Pro

2016 Drugs in R&D Controlled trial quality: uncertain

116. Characterisation of Population Pharmacokinetics and Endogenous Follicle-Stimulating Hormone (FSH) Levels After Multiple Dosing of a Recombinant Human FSH (FE 999049) in Healthy Women (PubMed)

Characterisation of Population Pharmacokinetics and Endogenous Follicle-Stimulating Hormone (FSH) Levels After Multiple Dosing of a Recombinant Human FSH (FE 999049) in Healthy Women The aim of this study was to characterise the population pharmacokinetics of FE 999049, a novel recombinant human follicle-stimulating hormone (FSH), after multiple dosing in healthy women, taking into account endogenous FSH levels and the reproductive hormone dynamics.Longitudinal measurements of FSH, luteinising (...) hormone, progesterone, estradiol, and inhibin B levels were collected after repeated subcutaneous dosing with 225 IU of FE 999049 in 24 gonadotropin downregulated healthy women. The FSH data were described using nonlinear mixed-effects modelling.The measured FSH levels were modelled as a sum of endogenous FSH and FE 999049. The FE 999049 population pharmacokinetics were best described using a one-compartment model with first-order absorption and elimination, and a transit model for delayed absorption

Full Text available with Trip Pro

2016 Drugs in R&D Controlled trial quality: uncertain

117. Oral follicle-stimulating hormone agonist tested in healthy young women of reproductive age failed to demonstrate effect on follicular development but affected thyroid function. (PubMed)

Oral follicle-stimulating hormone agonist tested in healthy young women of reproductive age failed to demonstrate effect on follicular development but affected thyroid function. To assess the safety, pharmacokinetics, and pharmacodynamics of MK-8389.Double-blind, placebo-controlled, parallel-group, ascending dose study.Two clinical research organizations.Healthy young women.Once-daily oral doses of MK-8389 or placebo for 14 days.Safety, including thyroid function tests (TFTs), pharmacokinetics (...) , and follicular development (follicle size and number and serum E2 and inhibin B levels).Treatment with MK-8389 was generally safe and well tolerated. An effect on TFTs was observed, which was transient and did not lead to clinical signs or symptoms but prevented dose escalation above 40 mg. MK-8389 was rapidly absorbed, slowly eliminated, and showed a large peak-to-trough ratio. No clinically meaningful effect was seen on follicle size and numbers, which was consistent with the low E2 levels. At doses >20 mg

2016 Fertility and Sterility Controlled trial quality: predicted high

118. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). (PubMed)

Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Pharmacokinetic studies with XM17 (Ovaleap®), a recombinant human follicle-stimulating hormone (r-hFSH, follitropin alfa), have demonstrated good safety and tolerability in healthy women whose endogenous FSH levels were down-regulated with a long agonist protocol. In these studies (...) favorable and comparable safety profiles, with no unexpected safety findings.Ovaleap® has shown the same efficacy and safety as Gonal-f® for stimulation of follicular development in infertile women (up to 37 years of age) who are undergoing ART therapy.EudraCT: 2009-017674-20. Current controlled trials: ISRCTN74772901 . Date of trial registration: 19 March 2010.

Full Text available with Trip Pro

2016 Reproductive biology and endocrinology : RB&E Controlled trial quality: predicted high

119. Comparing antral follicle count and serum anti-Mullerian hormone level for determination of gonadotrophin dosing in in-vitro fertilisation: a randomized trial. (PubMed)

Comparing antral follicle count and serum anti-Mullerian hormone level for determination of gonadotrophin dosing in in-vitro fertilisation: a randomized trial. To compare the proportion of women having a desired ovarian response following ovarian stimulation with gonadotrophin dosing determined based on AFC versus serum AMH level in women undergoing IVF using the GnRH antagonist protocol.This was a randomised double-blinded trial carried out in a university-affiliated assisted reproduction unit (...) %) groups (p=0.523). The median number of oocytes retrieved were 9 vs 7 (p=0.064), and the median follicular output rate (FORT) was 0.56 vs 0.55 (p=0.759) in the AFC and AMH groups respectively. The same conclusion applied to subgroup analyses on subjects with AFC<=5 and AFC>5 at commencement of ovarian stimulation (P>0.05 for all comparisons). There was moderate concordance between AFC and AMH measured in the pre-treatment cycle and the stimulation cycle (ĸ = 0.460 and 0.573 respectively).Gonadotrophin

2019 Ultrasound in Obstetrics and Gynecology Controlled trial quality: uncertain

120. Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield (PubMed)

Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield Unlike infertility, patients presenting for fertility preservation (FP) are often using combined hormonal contraceptives (CHC). We studied whether long-term (≥6 months) CHC use is associated with reversible suppression of antral follicle count (AFC).This is a longitudinal study of FP cycles from 2012 to 2016. We studied three (...) groups: those without CHC exposure (NO CHC), those with CHC usage with a CHC break (BREAK), and without a break (NO BREAK) prior to ovarian stimulation. We assessed ovarian reserve by AFC at initial consultation and discussed the possibility of CHC suppression of AFC. Patients chose between ovarian stimulation with no CHC break versus ovarian stimulation after a CHC break. AFC was measured serially in the BREAK group. We assessed whether AFC suppression was reversed in the BREAK group. Total oocyte

Full Text available with Trip Pro

2017 Journal of assisted reproduction and genetics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>